Kairos Pharma Ltd (KAPA) Total Debt to Capital
Kairos Pharma Ltd (KAPA) faces uncertainty regarding new drug test results and the search for partners, yet relies on a dedicated staff of scientists motivated by stock options. This chart of the total debt-to-equity ratio captures a value of 0.00. The business focuses on developing a targeted immune response system, which could radically shift therapy standards for lung and prostate tumors.
%20-%20Total%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_KAPA_-_Kairos-Pharma-Ltd_-_Total-Debt-to-Capital "Kairos Pharma Ltd (KAPA) Debt to Equity: for the period 09/17/2024 - 10/31/2026 | 👁️GURU.Markets👁️")
Metric breakdowns and analytics for Kairos Pharma (KAPA)
- share price and consensus valuation forecast:
- market capitalization details:
- book capitalization indicators:
- debt and liquidity details:
Total Debt to Capital Kairos Pharma Ltd|KAPA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Kairos Pharma Limited|KAPA - Aggregate Debt Obligations|Debt to Book Value Kairos Pharma|KAPA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Kairos Pharma|Quick Liquidity Indicator kairospharma.com
- net income and valuation ratios data:
Fundamental company valuation:Kairos Pharma Ltd
The implementation of AI in molecular design and the automation of drug synthesis at Kairos Pharma Ltd (KAPA) optimize drug development costs. The ratio of total liabilities to equity determines the degree of financial leverage, allowing an investor to assess the company's dependence on borrowed capital through changes in the proportion of total debt to equity.
Competitor analysis for Kairos Pharma Ltd
ONC (BeiGene) - Total Debt to Capital|Total Debt to Equity Ratio Halozyme Therapeutics, Inc. (HALO)|Total Debt to Capital RVMD|Total Debt to Capital Ascentage Pharma Corp (AAPG)|Debt to Equity CG Oncology, Inc. CGON|URGN: Debt to Equity Ratio|Bicara Therapeutics - Total Debt to Capital|Personalis Inc (PSNL) - Total Debt to Equity Ratio|ERAS: Total Debt to Capital|Debt to Capital Delcath Corp (DCTH)|Debt to Equity Y-mAbs Therapeutics|AURA: All Debt to Shareholders' Equity Ratio|Total Debt to Equity Ratio CADL (Candel Therapeutics)|ARAY (Accuray Inc) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital SLS (SELLAS Life Sciences Group)|ACTU - Total Debt to Equity Ratio|CTOR: Total Debt to Equity Ratio|HURA - Total Debt to Capital|Protara Therapeutics, Inc. (TARA) - Debt to Equity|Fate Therapeutics Inc - All Debt to Shareholders' Equity Ratio|WHWK (Aadi Bioscience, Inc.) - Total Debt to Capital|Debt to Capital TScan TCRX|Debt to Equity Champions Oncology (CSBR)|Total Debt to Capital xbiotech.com (XBIT)|Total Debt to Capital CVM (CEL-SCI)|Total Debt to Capital OS Therapies Inc. OSTX|Radiopharm Theranostics Limited - Total Debt to Capital|Total Debt to Capital Coefficient Artiva Biotherapeutics, Inc. ARTV|adlainortye.com (ANL) - Debt to Equity|verupharma.com - All Debt to Shareholders' Equity Ratio|Debt to Equity Tempest Therapeutics, Inc.|Debt to Capital Xilio XLO|Debt to Equity Renovaro Inc. (RENB)|Total Debt to Capital Coefficient muraloncology.com|OnKure Therapeutics - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio GDTC|CRIS - Debt to Equity|Aggregate Debt to Equity APLM|THAR: Total Debt to Capital|Advanced Biomed - All Debt to Shareholders' Equity Ratio|GNPX (Genprex, Inc.) - Total Debt to Capital|Total Debt to Capital Calidi Bio|Debt to Equity Sunshine Biopharma, Inc. (SBFM)|XBIO (xeneticbio.com) - All Debt to Shareholders' Equity Ratio|Debt to Equity Salarius SLRX|PPBT - Total Debt to Equity Ratio|AON - Total Debt to Capital|BGNE - Total Debt to Capital|CKPT (Checkpoint Therapeutics, Inc.) - Total Debt to Equity Ratio|elevationoncology.com - All Debt to Shareholders' Equity Ratio|Debt to Equity iCAD Inc.|Debt to Equity IKNA|Total Debt to Equity Ratio NTBL (Notable Labs, Ltd.)|Aggregate Debt to Capital VIRX|Total Debt to Capital MOR (MorphoSys)|NAYA: Debt to Equity Ratio|AAPGV - Debt to Equity